Stephanie Lovell Sells 1,193 Shares of TransMedics Group (NASDAQ:TMDX) Stock

TransMedics Group, Inc. (NASDAQ:TMDX) Director Stephanie Lovell sold 1,193 shares of the stock in a transaction dated Wednesday, March 4th. The shares were sold at an average price of $149.62, for a total transaction of $178,496.66. Following the sale, the director directly owned 2,866 shares in the company, valued at $428,810.92. This trade represents a 29.39% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.

TransMedics Group Stock Down 7.3%

NASDAQ:TMDX traded down $10.27 on Friday, reaching $129.80. 1,079,448 shares of the stock traded hands, compared to its average volume of 822,516. The company has a current ratio of 7.14, a quick ratio of 6.59 and a debt-to-equity ratio of 1.06. The company has a market capitalization of $4.45 billion, a price-to-earnings ratio of 26.49 and a beta of 1.98. TransMedics Group, Inc. has a 12 month low of $62.23 and a 12 month high of $156.00. The company’s fifty day simple moving average is $135.35 and its 200 day simple moving average is $126.90.

Institutional Investors Weigh In On TransMedics Group

A number of large investors have recently made changes to their positions in the company. Whittier Trust Co. of Nevada Inc. boosted its holdings in shares of TransMedics Group by 981.0% in the third quarter. Whittier Trust Co. of Nevada Inc. now owns 227 shares of the company’s stock worth $26,000 after buying an additional 206 shares during the last quarter. Salomon & Ludwin LLC purchased a new stake in TransMedics Group during the third quarter valued at approximately $28,000. Harvest Fund Management Co. Ltd bought a new position in TransMedics Group in the third quarter worth approximately $29,000. Optiver Holding B.V. boosted its stake in shares of TransMedics Group by 248.1% during the 3rd quarter. Optiver Holding B.V. now owns 268 shares of the company’s stock worth $30,000 after acquiring an additional 191 shares during the last quarter. Finally, Allworth Financial LP boosted its stake in shares of TransMedics Group by 74.3% during the 3rd quarter. Allworth Financial LP now owns 265 shares of the company’s stock worth $30,000 after acquiring an additional 113 shares during the last quarter. 99.67% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

TMDX has been the topic of several analyst reports. Piper Sandler upped their price objective on TransMedics Group from $140.00 to $160.00 and gave the company an “overweight” rating in a research report on Wednesday, February 25th. Needham & Company LLC upped their price target on TransMedics Group from $166.00 to $174.00 and gave the company a “buy” rating in a report on Wednesday, February 25th. JPMorgan Chase & Co. increased their price objective on TransMedics Group from $114.00 to $149.00 and gave the company a “neutral” rating in a research report on Wednesday, February 25th. Canaccord Genuity Group boosted their target price on TransMedics Group from $147.00 to $148.00 and gave the stock a “buy” rating in a research report on Wednesday, December 17th. Finally, Morgan Stanley upped their target price on shares of TransMedics Group from $123.00 to $135.00 and gave the company an “equal weight” rating in a research note on Tuesday, December 2nd. Six investment analysts have rated the stock with a Buy rating and five have given a Hold rating to the company’s stock. According to data from MarketBeat, TransMedics Group currently has an average rating of “Moderate Buy” and an average price target of $150.67.

TransMedics Group Company Profile

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.